Articles

Niraparib Efficacy in Advanced Ovarian Cancer Extends to All Biomarker Subgroups

ASCO guidelines cite significant improvement in progression-free survival when PARP inhibitors are used as maintenance therapy or in the setting of recurrent disease in women with advanced ovarian cancer who have responded to platinum-based chemotherapy in the first line. Read More ›

Olaparib/Bevacizumab as First-Line Maintenance Reduces Risk for Progression or Death in Patients with Advanced Ovarian Cancer

In an analysis of the phase 3 PRIMA study, niraparib monotherapy as first-line maintenance after platinum-based chemotherapy improved progression-free survival in women with newly diagnosed advanced ovarian cancer regardless of BRCA mutation status or homologous recombination status (deficient or proficient). Read More ›

Online Delivery of Genetic Services: No Increase in Cancer Risk Distress versus Telephone Counseling

In the PAOLA-1 study, women with advanced ovarian cancer, regardless of BRCA mutation status, experienced a 40% reduction in the risk for disease progression or death when randomized to olaparib plus bevacizumab compared with placebo and bevacizumab. The reduction in risk with olaparib was greatest in patients whose tumors were homologous recombination deficient. Read More ›

From The Editor TON October 2020

In a 4-arm randomized study, providing telephone genetic counseling only to those women who have a pathogenic mutation or who request the counseling is noninferior to mandatory pre- and posttest counseling, which may represent a new paradigm for genetic testing. Read More ›

By Catherine Bishop, DNP, NP-C, AOCNP

From the Editor

University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

I was very honored to be asked to take the reins as the new Editor-in-Chief of The Oncology Nurse-APN/PA (TON) by the founding Editor-in-Chief Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN. Although Beth will be a hard act to follow, I will do my best to maintain the high standards she has established for the journal Read More ›

Cancer Center Profile

Nursing Strategies for Optimizing Patient Care During the COVID-19 Pandemic

The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) in Baltimore is a National Cancer Institute–designated comprehensive cancer center, a distinction that places it in the top tier of cancer institutions in the United States. Read More ›

AVBCC COVID-19 Webcast Series, COVID-19

Germline Testing Offers Valuable Insights in the Treatment of Early-Onset and Advanced Cancers

During the COVID-19 pandemic, oncology nurses have been the cornerstone of healthcare services, whether they are on the front lines offering compassionate care or in a leadership role developing and implementing new policies to promote better patient outcomes. Read More ›

Biomarkers

Impact of COVID-19 on Cancer Screening and How We Can Get Back on Track

Results from 2 studies highlight the increasingly important role of germline testing in the management of patients with cancer. These findings were presented by Zsofia K. Stadler, MD, Medical Oncologist, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York City. Read More ›

COVID-19